Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Research by M.L. Sorror and colleagues in acute myeloid leukemia provides new insights
March 2nd, 2008
"A new hematopoietic cell transplantation-specific comorbidity index (HCT-Cl) was effective in predicting outcomes among patients with hematologic malignancies who underwent HCT at Fred Hutchinson Cancer Research Center (FHCRC). Here, we compared the performance of the HCT-Cl to 2 other indices and then tested its capacity to predict outcomes among 2 cohorts of patients diagnosed with a single disease entity, acute myeloid leukemia in first complete remission, who underwent transplantation at either FHCRC or M. D. Anderson Cancer Center (MDACC)," scientists in the United States report. "FHCRC patients less frequently had unfavorable cytogenetics (15% versus 36%) and...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-02)
|
